Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients With Diabetes Mellitus - DECLARE-DIABETES


Diabetic patients have a higher rate of restenosis following the implantation of coronary stents, compared with nondiabetics, even with drug-eluting stents (DES). The goal of this trial was to compare the effect of cilostazol, a phosphodiesterase inhibitor, with antiproliferative properties, in addition to aspirin and clopidogrel, on in-stent restenosis in diabetic patients undergoing implantation of DES.